专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5079237A Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin and a sustained release pharmaceutical preparation containing the same 失效
标题翻译：包括尼卡地平或其盐酸盐与β-环糊精的复合物和含有其的持续释放药物制剂
公开(公告)号：US5079237A
公开(公告)日：1992-01-07
申请号：US298151
申请日：1989-01-18
申请人： Breda Husu , Jenny Milovac , Zdravko Kopitar , Branko Huc , Janko Zmitek , Peter Bukovec , Mirjan Zorz , Boris Rusjakovski , Polona Cvelbar , Zdenka Jerala-Strukelj , Bojan Kofler
发明人： Breda Husu , Jenny Milovac , Zdravko Kopitar , Branko Huc , Janko Zmitek , Peter Bukovec , Mirjan Zorz , Boris Rusjakovski , Polona Cvelbar , Zdenka Jerala-Strukelj , Bojan Kofler
IPC分类号： C07D211/90 , A61K31/44 , A61K31/455 , A61K47/40 , A61K47/48 , A61P9/08 , A61P9/10 , A61P9/12 , C08B37/00
CPC分类号： B82Y5/00 , A61K31/44 , A61K47/48969 , C08B37/0015 , Y10S514/929 , Y10S514/964
摘要： There is described a new inclusion complex of nicardipine or its hydrochloride with beta-cyclohdextrin, which is prepared by admixing nicardipine or its hydrochloride with beta-cyclodextrin in a molar ratio of the compounds 1:0.9-1.1 under stirring at a temperature from about room temperature to the boiling temperature of the reaction mixture in an aqueous or ethanolic medium, cooling the reaction mixture to 0.degree. to 5.degree. C. and isolating the desired complex.The inclusion complex of nicardipine or its hydrochloride posesses cerebrovascular-vasodilatory and coronary-vasodilatory properties, which are equally well expressed as those of nicardipine or its hydrochloride themselves, yet owing to the better solubility of the complex at a higher pH range, such as it exists e.g. in the intestinal tract, the manufacture of sustained release pharmaceutical forms is made possible, whereby a greater extent of dissolution of the active substance is provided also in the intestinal juice.

2. 发明授权

US5624597A Reagent compositions for analytical testing 失效
标题翻译：用于分析测试的试剂组合物
公开(公告)号：US5624597A
公开(公告)日：1997-04-29
申请号：US436670
申请日：1995-05-08
申请人： Steven N. Buhl , Terri Bogart , Tammy Burd , Bhaskar Bhayani , Christian Skieller , Chi-Sou Yu , Thuy N. Tang , Vladimir E. Ostoich , Branko Huc , Carol T. Schembri
发明人： Steven N. Buhl , Terri Bogart , Tammy Burd , Bhaskar Bhayani , Christian Skieller , Chi-Sou Yu , Thuy N. Tang , Vladimir E. Ostoich , Branko Huc , Carol T. Schembri
IPC分类号： C12Q1/32 , A61K9/16 , C12Q1/42 , G01N1/10 , G01N9/30 , G01N21/78 , G01N33/48 , G01N33/483 , G01N33/49 , G01N33/50 , G01N33/52 , G01N33/53 , G01N33/58 , G01N33/68 , G01N35/00 , C09K3/00 , G01N31/00
CPC分类号： G01N33/52 , A61K9/1694 , C12Q1/42 , G01N33/491 , G01N33/50 , G01N33/585 , G01N33/68 , Y10S436/805 , Y10S436/808 , Y10T436/10 , Y10T436/111666
摘要： The present invention provides lyophilized reagent spheres comprising reagents suitable for analysis of biological samples, in particular analysis of blood samples in centrifugal analyzers. Also provided are diluents which are conveniently used in such analyzers.
摘要翻译：本发明提供了冻干试剂球，其包含适于分析生物样品的试剂，特别是离心分析仪中血液样品的分析。还提供了在这种分析仪中方便使用的稀释剂。

3. 发明授权

US5266560A Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity 失效
公开(公告)号：US5266560A
公开(公告)日：1993-11-30
申请号：US756531
申请日：1991-09-09
申请人： Sydney C. Furman , Charles T. Goetschel , Branko Huc , Thomas H. Nufert
发明人： Sydney C. Furman , Charles T. Goetschel , Branko Huc , Thomas H. Nufert
IPC分类号： A61K31/555 , C07F11/00 , C07D213/89
CPC分类号： C07F11/005 , A61K31/555 , Y10S514/866
摘要： A composition of matter having GTF-like activity, its preparation and its use in treating chromium deficiency and insulin resistance diseases such as diabetes are set forth. The composition comprises: ##STR1## m=1, 2 or 3; n=0, 1 or 2; p=0, 1, 2, 3, 4 or 5; q=0, 1, 2, 3, 4 or 5; r=0, 1, 2 or 3;m+2n+p+q+r.ltoreq.6;if p and q both=0, n=1 pr z;if n=0, p and/or q.noteq.0;including mixtures and oligomers thereof, wherein:each R.sup.1 is independently selected from hydrogen, C.sub.1-3 alkyl, C.sub.2-3 alkenyl and C.sub.2-3 alkynyl, or two R.sup.1 form a ring having, including the N atom to which they are attached, 5 to 7 ring atoms;each R.sup.2 is independently selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl and C.sub.2-4 alkynyl or two adjacent R.sup.1 and R.sup.2 form a ring having, including the N and C atoms to which they are attached, 5 to 7 ring atoms;each R.sup.3 is independently selected from hydrogen, fluoro, chloro, bromo, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, COOH, COOR.sup.6, CHO or COR.sup.6, wherein R.sup.6 is selected from C.sub.1-4 alkyl, C.sub.2-4 alkenyl and C.sub.2-4 alkynyl or two adjacent R.sup.3 from a ring having, including the atoms of the aromatic nitrogen containing ring to which they are attached, 5 to 7 ring atoms;R.sup.7 is CN or CR.sub.2.sup.8 OH, CR.sub.2.sup.8 SH, or CR.sub.2.sup.8 NH.sub.2, wherein each R.sup.8 is independently H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, or COX, CSX or CNHX, wherein each X is independently H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OY, NR.sub.2.sup.4 or SY, wherein Y is hydrogen, alkyl, an alkali metal or ammonium ion and each R.sup.4 is independently selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, or two geminal R.sup.4 form a ring having, including the nitrogen atom to which they are attached, 5-7 ring atoms;and each R is independently selected such that R.sub.2.sup.1 NCRR.sup.2 COOH is an amino acid or a peptide having no more than 6 amino acid residues, optionally having one or more of the substituents SH, NH.sub.2, OH, COOH, CH.sub.2 OH, OCH.sub.3, OC.sub.2 H.sub.5, SCH.sub.3, SC.sub.2 H.sub.5, NH, Cl, Br, F, CCH or CN.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式